Genmab and Seagen Announced That TIVDAK Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
Portfolio Pulse from Charles Gross
Genmab A/S (GMAB) and Seagen Inc. (SGEN) announced that the Phase 3 innovaTV 301 global trial of TIVDAK in recurrent or metastatic cervical cancer patients met its primary endpoint of overall survival. The trial also demonstrated statistical significance in key secondary endpoints. The safety profile of TIVDAK was consistent with known information and no new safety signals were observed.
September 04, 2023 | 7:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's TIVDAK met its primary endpoint in a Phase 3 trial, potentially leading to increased demand for the drug.
Positive trial results often lead to increased demand for a drug, which could boost Genmab's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Seagen's TIVDAK met its primary endpoint in a Phase 3 trial, potentially leading to increased demand for the drug.
Positive trial results often lead to increased demand for a drug, which could boost Seagen's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100